Wayne D Tilley

List of Publications by Year
in descending order

181	11,966	18436 62	32761 100
papers	citations	h-index	g-index

195	195	195	15430
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. Cancer Research Communications, 2022, 2, 706-724.	0.7	3
2	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264
3	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Reports, 2021, 34, 108585.	2.9	33
4	The androgen receptor is a tumor suppressor in estrogen receptorâ€“positive breast cancer. Nature Medicine, 2021, 27, 310-320.	15.2	122
5	A cell permeable bimane-constrained PCNA-interacting peptide. RSC Chemical Biology, 2021, 2, 1499-1508.	2.0	5
6	ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Research, 2021, 81, 1704-1718.	0.4	44
7	Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes. Cancers, 2021, 13, 3272.	1.7	14
8	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. SLAS Discovery, 2021, 26, 1107-1124.	1.4	30
9	Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer. British Journal of Cancer, 2021, 125, 1599-1601.	2.9	6
10	Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. Cancer Research, 2021, 81, 4981-4993.	0.4	43
11	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology, 2021, 23, 1023-1034.	4.6	72
12	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 2021, 12, 6377.	5.8	16
13	Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor. Journal of Steroid Biochemistry and Molecular Biology, 2020, 199, 105548.	1.2	12
14	Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discovery Today, 2020, 25, 406-413.	3.2	140
15	Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 2020, 76, 976-987.	1.6	18
16	Jean Wilson and His Legacy, 50 Years and Counting. Urology, 2020, 153, 1-5.	0.5	0
17	Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo. Frontiers in Cell and Developmental Biology, 2020, 8, 599.	1.8	14
18	MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Research, 2020, 22, 87.	2.2	37

#	Article	IF	Citations
19	Endonuclease FEN1 Coregulates ERÎ± Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer. Cancer Research, 2020, 80, 1914-1926.	0.4	23
20	Androgen Receptor Signalling Promotes a Luminal Phenotype in Mammary Epithelial Cells. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 99-108.	1.0	7
21	Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. Journal of Medicinal Chemistry, 2019, 62, 4233-4251.	2.9	162
22	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene, 2019, 38, 1136-1150.	2.6	15
23	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 2019, 144, 1151-1159.	2.3	13
24	Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocrine-Related Cancer, 2019, 26, 251-264.	1.6	29
25	Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer. Endocrine-Related Cancer, 2019, 26, R237-R257.	1.6	20
26	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research, 2018, 24, 2328-2341.	3.2	63
27	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	0.9	105
28	New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030478.	2.9	19
29	Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-Î± and progesterone receptor-b. British Journal of Cancer, 2018, 119, 1316-1325.	2.9	9
30	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	0.9	80
31	A patientâ€derived explant (<scp>PDE</scp>) model of hormoneâ€dependent cancer. Molecular Oncology, 2018, 12, 1608-1622.	2.1	94
32	miRâ€200/375 control epithelial plasticityâ€associated alternative splicing by repressing the <scp>RNA</scp> â€binding protein Quaking. EMBO Journal, 2018, 37, .	3.5	82
33	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. European Urology Oncology, 2018, 1, 325-337.	2.6	37
34	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
35	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
36	Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. Cancer Research, 2017, 77, 3417-3430.	0.4	79

#	Article	IF	Citations
37	Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelialâ€“Mesenchymal Plasticity in Prostate Cancer. Cancer Research, 2017, 77, 3101-3112.	0.4	68
38	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Research, 2017, 77, 1021-1034.	0.4	94
39	Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Research, 2017, 77, 6282-6298.	0.4	62
40	Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. Molecular and Cellular Endocrinology, 2017, 440, 138-150.	1.6	91
41	Deciphering the divergent roles of progestogens in breast cancer. Nature Reviews Cancer, 2017, 17, 54-64.	12.8	96
42	Novel twists in hormone-mediated carcinogenesis. Endocrine-Related Cancer, 2016, 23, E9-E12.	1.6	0
43	Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice. Scientific Reports, 2016, 6, 28950.	1.6	11
44	Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Science Advances, 2016, 2, e1501924.	4.7	100
45	Pushing estrogen receptor around in breast cancer. Endocrine-Related Cancer, 2016, 23, T227-T241.	1.6	35
46	Renewed interest in the progesterone receptor in breast cancer. British Journal of Cancer, 2016, 115, 909-911.	2.9	28
47	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17. Cancer Research, 2016, 76, 5881-5893.	0.4	50
48	Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocrine-Related Cancer, 2016, 23, T179-T197.	1.6	132
49	Î²BÎ± mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 2016, 16, 141.	1.1	10
50	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Journal of the National Cancer Institute, 2016, 108, djv371.	3.0	37
51	Regulators of genetic risk of breast cancer identified by integrative network analysis. Nature Genetics, 2016, 48, 12-21.	9.4	163
52	Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer, 2015, 22, 805-818.	1.6	24
53	Progesterone receptor modulates ERÎ± action in breast cancer. Nature, 2015, 523, 313-317.	13.7	504
54	Expression and localisation of c-kit and KITL in the adult human ovary. Journal of Ovarian Research, 2015, 8, 31.	1.3	22

#	Article	IF	Citations
55	Hormone-Sensing Mammary Epithelial Progenitors: Emerging Identity and Hormonal Regulation. Journal of Mammary Gland Biology and Neoplasia, 2015, 20, 75-91.	1.0	12
56	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Research, 2015, 43, 5880-5897.	6.5	136
57	Mouse GDF9 decreases KITL gene expression in human granulosa cells. Endocrine, 2015, 48, 686-695.	1.1	6
58	Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget, 2015, 6, 44728-44744.	0.8	77
59	PRMT2 and RORÎ³ Expression Are Associated With Breast Cancer Survival Outcomes. Molecular Endocrinology, 2014, 28, 1166-1185.	3.7	45
60	Tailoring Peptidomimetics for Targeting Proteinâ€“Protein Interactions. Molecular Cancer Research, 2014, 12, 967-978.	1.5	41
61	Bringing androgens up a NOTCH in breast cancer. Endocrine-Related Cancer, 2014, 21, T183-T202.	1.6	24
62	Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. Menopause, 2014, 21, 79-88.	0.8	17
63	Androgen signalling and steroid receptor crosstalk in endocrine cancers. Endocrine-Related Cancer, 2014, 21, E3-E5.	1.6	5
64	Complexities of androgen receptor signalling in breast cancer. Endocrine-Related Cancer, 2014, 21, T161-T181.	1.6	113
65	Breast cancer prognosis predicted by nuclear receptorâ€coregulator networks. Molecular Oncology, 2014, 8, 998-1013.	2.1	27
66	Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues. Hormones and Cancer, 2014, 5, 61-71.	4.9	60
67	Epithelial plasticity in prostate cancer: principles and clinical perspectives. Trends in Molecular Medicine, 2014, 20, 643-651.	3.5	21
68	Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocrine-Related Cancer, 2014, 21, L17-L21.	1.6	34
69	Estrogen receptor beta in prostate cancer: friend or foe?. Endocrine-Related Cancer, 2014, 21, T219-T234.	1.6	85
70	Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget, 2014, 5, 8651-8664.	0.8	22
71	Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 2013, 73, 182-193.	1.2	17
72	SGTA: A New Player in the Molecular Co-Chaperone Game. Hormones and Cancer, 2013, 4, 343-357.	4.9	30

#	Article	IF	Citations
73	Updates from the Editors. Hormones and Cancer, 2013, 4, 121-122.	4.9	0
74	Androgen Receptor Protein Levels Are Significantly Reduced in Serous Ovarian Carcinomas Compared with Benign or Borderline Disease but Are Not altered by Cancer Stage or Metastatic Progression. Hormones and Cancer, 2013, 4, 154-164.	4.9	20
75	Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. BMC Biochemistry, 2013, 14, 10.	4.4	14
76	Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 2013, 133, 2812-2823.	2.3	21
77	Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Research and Treatment, 2013, 142, 211-223.	1.1	45
78	Small glutamine-rich tetratricopeptide repeatâ€“containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome. Fertility and Sterility, 2013, 99, 2076-2083.e1.	0.5	5
79	Hsp90: Still a viable target in prostate cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1835, 211-218.	3.3	32
80	Ex vivo culture of human prostate tissue and drug development. Nature Reviews Urology, 2013, 10, 483-487.	1.9	111
81	Peptidomimetic targeting of critical androgen receptorâ€“coregulator interactions in prostate cancer. Nature Communications, 2013, 4, 1923.	5.8	125
82	Identification of Prostate Cancer-Associated MicroRNAs in Circulation Using a Mouse Model of Disease. Methods in Molecular Biology, 2013, 1024, 235-246.	0.4	3
83	Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast Cancer. Molecular Endocrinology, 2013, 27, 350-365.	3.7	98
84	Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 2013, 4, 691-704.	0.8	57
85	Abstract B047: Cyclin-dependent kinase 2 regulates androgen receptor activity in estrogen receptor negative breast cancer. , 2013, , .		0
86	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal, 2012, 31, 1617-1617.	3.5	2
87	Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Journal of Molecular Endocrinology, 2012, 49, 57-68.	1.1	19
88	Research Resource: Interplay between the Genomic and Transcriptional Networks of Androgen Receptor and Estrogen Receptor Î± in Luminal Breast Cancer Cells. Molecular Endocrinology, 2012, 26, 1941-1952.	3.7	80
89	Circulating microRNAs: macro-utility as markers of prostate cancer?. Endocrine-Related Cancer, 2012, 19, R99-R113.	1.6	40
90	Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocrine-Related Cancer, 2012, 19, 509-526.	1.6	37

#	Article	IF	Citations
91	Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discovery, 2012, 2, 1134-1149.	7.7	354
92	An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer, 2012, 19, 599-613.	1.6	51
93	Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle, 2012, 11, 2756-2761.	1.3	201
94	Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors. Clinical Cancer Research, 2012, 18, 3562-3570.	3.2	92
95	Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer, 2012, 131, 652-661.	2.3	169
96	A gene signature identified using a mouse model of androgen receptorâ€dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer, 2012, 131, 662-672.	2.3	33
97	Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology, 2012, 357, 60-70.	1.6	42
98	Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Molecular and Cellular Endocrinology, 2011, 342, 20-31.	1.6	15
99	Specific medical conditions associated with clinically significant depressive symptoms in men. Social Psychiatry and Psychiatric Epidemiology, 2011, 46, 1303-1312.	1.6	26
100	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal, 2011, 30, 3019-3027.	3.5	247
101	GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2â€²-Deoxycytidine Efficacy in Human Prostate Cancer Cells. PLoS ONE, 2011, 6, e25634.	1.1	49
102	Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncology Reports, 2010, 23, 1045-52.	1.2	14
103	Serum testosterone bioassay evaluation in a large male cohort. Clinical Endocrinology, 2010, 72, 87-98.	1.2	5
104	Breast and prostate cancer: more similar than different. Nature Reviews Cancer, 2010, 10, 205-212.	12.8	212
105	Circulating Steroid Hormone Levels and Risk of Breast Cancer for Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 492-502.	1.1	94
106	A Novel Polymorphism in a Forkhead Box A1 (FOXA1) Binding Site of the Human UDP Glucuronosyltransferase 2B17 Gene Modulates Promoter Activity and Is Associated with Altered Levels of Circulating Androstane-3Î±,17Î²-diol Glucuronide. Molecular Pharmacology, 2010, 78, 714-722.	1.0	30
107	Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1755-1765.	1.1	13
108	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2611-2622.	1.1	145

#	Article	IF	Citations
109	Androgen Receptor Inhibits Estrogen Receptor-Î± Activity and Is Prognostic in Breast Cancer. Cancer Research, 2009, 69, 6131-6140.	0.4	329
110	Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2009, 2, 619-630.	1.3	5
111	A Novel Androgen Receptor Amino Terminal Region Reveals Two Classes of Amino/Carboxyl Interaction-Deficient Variants with Divergent Capacity to Activate Responsive Sites in Chromatin. Endocrinology, 2009, 150, 2674-2682.	1.4	26
112	The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 104-109.	3.3	12
113	Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Research and Treatment, 2009, 115, 171-179.	1.1	113
114	Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate, 2009, 69, 761-769.	1.2	16
115	Insights from AR Gene Mutations. , 2009, , 207-240.		2
116	Elevated levels of HERâ€2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate, 2008, 68, 830-838.	1.2	43
117	Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology, 2008, 110, 236-243.	1.2	65
118	Minireview: The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 2008, 22, 2373-2382.	3.7	121
119	Immunohistochemical Level of Unsulfated Chondroitin Disaccharides in the Cancer Stroma Is an Independent Predictor of Prostate Cancer Relapse. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2488-2497.	1.1	24
120	Expression of Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (Î±SGT), a Novel Regulator of Androgen Receptor (AR) Activity, in the Human Ovary and Fallopian Tube.. Biology of Reproduction, 2008, 78, 295-295.	1.2	0
121	Functional Androgen Signaling in an Explant Model of Normal Human Breast Tissue.. Biology of Reproduction, 2008, 78, 142-142.	1.2	0
122	Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility. Journal of Biological Chemistry, 2007, 282, 10814-10825.	1.6	126
123	Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 763-768.	1.1	93
124	Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamineâ€"Rich Tetratricopeptide Repeat Containing Protein Î±. Cancer Research, 2007, 67, 10087-10096.	0.4	82
125	Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular Cancer Therapeutics, 2007, 6, 51-60.	1.9	103
126	Role of oncoprotein Growth Factor Independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): A comparative analysis in human prostate cancer and kidney cells. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 742-746.	1.2	10

#	Article	IF	Citations
127	Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Molecular and Cellular Endocrinology, 2007, 268, 67-74.	1.6	9
128	Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB Journal, 2007, 21, 2285-2293.	0.2	76
129	Identification of novel androgen receptor target genes in prostate cancer. Molecular Cancer, 2007, 6, 39.	7.9	88
130	Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. International Journal of Cancer, 2007, 120, 719-733.	2.3	209
131	5Î±-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. International Journal of Cancer, 2007, 120, 776-780.	2.3	53
132	Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation. Prostate, 2007, 67, 288-300.	1.2	11
133	Non-linear chromosomal inversion response in prostate after low dose X-radiation exposure. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006, 602, 65-73.	0.4	41
134	The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. International Journal of Cancer, 2006, 119, 944-954.	2.3	68
135	Suppression of Androgen Receptor Signaling in Prostate Cancer Cells by an Inhibitory Receptor Variant. Molecular Endocrinology, 2006, 20, 1009-1024.	3.7	17
136	Circulating Steroid Hormones and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 86-91.	1.1	159
137	Variants in the Prostate-Specific Antigen (PSA) Gene and Prostate Cancer Risk, Survival, and Circulating PSA. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1142-1147.	1.1	24
138	Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1137-1141.	1.1	59
139	Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate, 2005, 63, 19-28.	1.2	103
140	Androgen metabolic genes in prostate cancer predisposition and progression. Frontiers in Bioscience - Landmark, 2005, 10, 2892.	3.0	6
141	Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1151-1156.	3.3	164
142	GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biological Chemistry, 2005, 386, 69-74.	1.2	29
143	Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate. Cancer Research, 2005, 65, 8487-8496.	0.4	58
144	Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer. Clinical Cancer Research, 2004, 10, 2491-2498.	3.2	129

#	Article	IF	Citations
145	Androgen Receptor Signaling. Cancer Research, 2004, 64, 2619-2626.	0.4	74
146	Structural and functional consequences of glutamine tract variation in the androgen receptor. Human Molecular Genetics, 2004, 13, 1677-1692.	1.4	182
147	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 2004, 11, 459-476.	1.6	212
148	Cancer-associated genes can affect somatic intrachromosomal recombination early in carcinogenesis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 550, 1-10.	0.4	11
149	Apolipoprotein-D: A novel cellular marker for HGPIN and prostate cancer. Prostate, 2004, 58, 103-108.	1.2	32
150	PC-3 cells with enhanced androgen receptor signaling: A model for clonal selection in prostate cancer. Prostate, 2004, 60, 352-366.	1.2	33
151	Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival. Cancer Gene Therapy, 2003, 10, 611-625.	2.2	9
152	ELAC2/HPC2 Polymorphisms, Prostate-Specific Antigen Levels, and Prostate Cancer. Journal of the National Cancer Institute, 2003, 95, 818-824.	3.0	53
153	Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucleic Acids Research, 2003, 31, 6741-6747.	6.5	35
154	Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Molecular Cancer Research, 2003, 1, 385-92.	1.5	50
155	Modulation of prostate cancer cell attachment to matrix by versican. Cancer Research, 2003, 63, 4786-91.	0.4	65
156	A Novel Androgen Receptor Mutant, A748T, Exhibits Hormone Concentration-Dependent Defects in Nuclear Accumulation and Activity Despite Normal Hormone-Binding Affinity. Molecular Endocrinology, 2002, 16, 2692-2705.	3.7	19
157	Contribution of the androgen receptor to prostate cancer predisposition and progression. , 2002, , 71-87.		0
158	Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer and Metastasis Reviews, 2001, 20, 207-223.	2.7	146
159	Mutations at the Boundary of the Hinge and Ligand Binding Domain of the Androgen Receptor Confer Increased Transactivation Function. Molecular Endocrinology, 2001, 15, 46-56.	3.7	105
160	Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer. Journal of Biological Chemistry, 2001, 276, 11204-11213.	1.6	111
161	Androgen receptor expression in primary prostate cancers of lobund-wistar rats and in tumor-derived cell lines. In Vitro Cellular and Developmental Biology - Animal, 1999, 35, 655-662.	0.7	6
162	Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Molecular and Cellular Endocrinology, 1999, 154, 11-20.	1.6	97

#	Article	IF	Citations
163	MOLECULAR DETECTION OF PROSTATE CELLS IN EJACULATE AND URETHRAL WASHINGS IN MEN WITH SUSPECTED PROSTATE CANCER. Journal of Urology, 1999, 161, 1337-1343.	0.2	32
164	IMMUNOLOCALIZATION OF APOLIPOPROTEIN D, ANDROGEN RECEPTOR AND PROSTATE SPECIFIC ANTIGEN IN EARLY STAGE PROSTATE CANCERS. Journal of Urology, 1998, 159, 548-554.	0.2	23
165	Vascular Endothelial Growth Factor (VEGF) Expression in Prostate Cancer and Benign Prostatic Hyperplasia. Journal of Urology, 1997, 157, 2323-2328.	0.2	157
166	Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids, 1995, 60, 180-186.	0.8	45
167	Differential Expression of Apolipoprotein-D and Prostate Specific Antigen in Benign and Malignant Prostate Tissues. Journal of Urology, 1995, 154, 622-628.	0.2	32
168	Glycosaminoglycans of guinea pig prostate fibromuscular stroma: Influence of estrogen and androgen on levels and location of chondroitin sulfate. Prostate, 1994, 25, 320-332.	1.2	13
169	Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells. International Journal of Cancer, 1992, 52, 778-784.	2.3	46
170	Androgen Resistance Associated with a Mutation of the Androgen Receptor at Amino Acid 772 (Argâ†'Cys) Results from a Combination of Decreased Messenger Ribonucleic Acid Levels and Impairment of Receptor Function*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 318-325.	1.8	65
171	Definition of the Human Androgen Receptor Gene Structure Permits the Identification of Mutations that Cause Androgen Resistance: Premature Termination of the Receptor Protein at Amino Acid Residue 588 Causes Complete Androgen Resistance. Molecular Endocrinology, 1990, 4, 1105-1116.	3.7	154
172	Antipeptide Antibodies to Two Distinct Regions of the Androgen Receptor Localize the Receptor Protein to the Nuclei of Target Cells in the Rat and Human Prostate*. Endocrinology, 1990, 126, 2359-2368.	1.4	171
173	Recent studies of the androgen receptor: new insights into old questions. Molecular and Cellular Endocrinology, 1990, 68, C7-C10.	1.6	21
174	Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. In Vitro Cellular & Developmental Biology, 1989, 25, 1016-1024.	1.0	29
175	Effect of pubertal development on estrogen receptor levels and stromal morphology in the guinea pig prostate. Prostate, 1989, 15, 195-210.	1.2	22
176	STEROID HORMONE AND EPIDERMAL GROWTH FACTOR RECEPTORS IN MENINGIOMAS. ANZ Journal of Surgery, 1989, 59, 881-888.	0.3	18
177	Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma. Prostate, 1987, 11, 271-279.	1.2	54
178	Specific binding of oestradiol to guinea-pig prostate cytosol and nuclear fractions. The Journal of Steroid Biochemistry, 1985, 22, 705-711.	1.3	7
179	Distribution of oestrogen and androgen receptors between the stroma and epithelium of the guinea-pig prostate. The Journal of Steroid Biochemistry, 1985, 22, 713-719.	1.3	28
180	Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 0, , 5.	0.2	2

#	Article	IF	Citations
181	Androgens and the androgen receptor (AR). , 0, , 378-391.		0